U.S. FDA approves first mRNA flu shot from Moderna
Summary
The shot, mFlusiva, was given a traditional approval for adults aged 50 to 64, and an accelerated approval for those 65 years and older
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For India, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketIndia
- ImpactMedium (50/100)
- SignalNews